Alzheimer"scloth festival wristbands drug in China shows promiseIt"s Not Too Early Start Off Scrapbooking For Christmas Gifts There are a handful of ornaments that are handed down in families, and you"ll realize there are some that any family buys as it grows. Likely to be decorate your tree, it is usually nice undertake a new decoration to mix. Here are some places to assist you to look for the new decoration. Mother"s day is finally here and your own mother expects that you get her a gift. It shouldn"t be costly gift however, you should attempt to offer your mother one of the most. All need to is to obtain online as well as will find whatever gift you should. Ladies fashion watch is certainly those cool gifts that could be liked by every great women. Gifts thorough dads ordinarily are not as easy, but they"ve made a physique on the market recently. Items such as being the Daddy Survival Gifts are very practical nicely add just a hint of humor. The company has been a long standing joke that men have trouble changing diapers so these cute new father gifts include items for being a clothes pin for their nose, dirty diaper changing guides as well gifts for brand new dads. Vino these gifts help dad function subsequent to the new baby arrives, they also include them in the process, it"s the transition easier.
A Chinese pharmaceutical firm has surged ahead of the US and Europe to develop and approve an Alzheimer"s drug that could help the cognitive functions of patients with a mild form of the disease.
The drug Oligomannate, a product of Shanghai-based Green Valley Pharmaceuticals, was given conditional approval Saturday by China"s National Medical Products Administration.
Research into the drug"s efficacy is still needed and it could be withdrawn if safety issues arise, the organization said.
The Chinese breakthrough comes after major US pharmaceutical firms Johnson & Johnson, Merck, Pfizer and Eli Lilly recently abandoned projects to develop a drug for Alzheimer"s over safety issues. Over nearly 20 years, there have been 400 clinical trials and billions of US dollars spent trying to find a cure.
The new drug will be the first approved in 17 years to treat the degenerative disease. Green Valley said Oligomannate would be released in China by the end of 2019. The company will then carry out phase three trials abroad in 2020 and later seek approval to market the drug in the US and Europe.
Dr Maria C. Carrillo, chief science officer at the Alzheimer"s Association, told China Daily in a statement: "On behalf of the tens of millions worldwide living with Alzheimer"s disease, the Alzheimer"s Association acknowledges and welcomes the announcement that China"s National Medical Products Administration conditionally approved the seaweed-based drug Oligomannate for mild to moderate Alzheimer"s dementia.""
Oligomannate, taken orally, is made from extracts of brown algae as raw material and works by suppressing certain bacteria in the gut that causes neural degeneration and inflammation in the brain. It was jointly developed by the Chinese Academy of Sciences" Shanghai Institute of Materia Medica, Green Valley and Ocean University.
During trials, it was tested on 818 people, but doctors warn it may not cure patients whose brains had degenerated beyond repair, or who wandered or needed help using the bathroom or bathing.
"Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit," Green Valley Pharmaceuticals said in a statement.
Alzheimer"s disease starts with memory loss and impacts cognitive ability. To date, there is no cure. Those aged 65 and up are at particular risk, but around 200,000 people aged below 65 have the disease.
In China, 9.5 million people have Alzheimer"s, amid a rapidly aging population. In the US, more than 5.8 million live with it, according to the Alzheimer"s Association. It is the country"s sixth-leading cause of death among those age 65 and older.
In August, Beijing overhauled its drug laws by allowing conditional approval for some medicines with "predictable" clinical value for life-threatening diseases where treatment was not available, Reuters reported.
Professor Zhang Zhenxin, a leading principal investigator of the phase three trial of Oligomannate and professor of neurology at Peking Union Medical College Hospital in Beijing told Pharmaletter: "The result of the nine-month trial of Oligomannate is exciting."
Finding a cure for Alzheimer"s has been a costly road with many failures. But last month, Biogen, based in Cambridge, Massachusetts, said next year it would seek approval from the Federal Drug Administration to market its drug aducanumab, which it said could help slow the effects of the disease.
"A cure is possible. We know enough about what"s going on at the cellular level," Hunter K. Anstine, chief development officer for the Alzheimer"s Research Foundation, told China Daily. "This is not trying to figure out how the universe was created; this is a reasonable thing to figure out and conquer. We just need to put a lot of resources into it."wholesale rubber braceletscoloured wristbandsbuy rubber wristbands online indiabig rubber braceletsathletic silicone wristbands